ARTICLE | Clinical News
ALD-401: Phase II ongoing
May 21, 2012 7:00 AM UTC
Cytomedix said an independent DSMB recommended continuation of the double-blind, placebo-controlled, U.S. Phase II RECOVER-Stroke trial based on a review of safety data from the first 10 patients. The...